

**March 2026**

**MEDPACE**  
Clinical Pharmacology

**SRK-439-001 SAD Cohort 5 Sentinels & Non-Sentinels**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>
<b>8</b>	<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>	<b>13</b>	<b>14</b>
<b>15</b>	<b>16</b>	<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b> Screening MRI Window Opens* Screening MRI Window Opens*	<b>21</b>
<b>22</b>	<b>23</b>	<b>24</b>	<b>25</b>	<b>26</b>	<b>27</b>	<b>28</b>
<b>29</b>	<b>30</b> Begin medication restrictions	<b>31</b> Begin medication restrictions				

**Study Inpatient dates:**

Sentinels: Apr 13-17, 2026  
Non-Sentinels: Apr 14-18, 2026

**Study Outpatient dates:**

Sentinels: Apr 21 and 28, 2026  
May 05, 12, 26, 2026  
Jun 09, Jul 07, Aug 04, Sep 01, Sep 29, 2026  
Non-Sentinels: Apr 22 and 29, 2026  
May 06, 13, 27, 2026  
Jun 10, Jul 08, Aug 05, Sep 02, Sep 30, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to Admission (Day -1) and required study visits (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI: A staff member from Cincinnati Children’s will contact you with further details.**

**April 2026**

**MEDPACE**  
Clinical Pharmacology

**SRK-439-001 SAD Cohort 5 Sentinels & Non-Sentinels**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			<b>1</b>	<b>2</b>	<b>3</b> Screening MRI Window Closes*	<b>4</b>
<b>5</b>	<b>6</b> Screening MRI Window Closes*	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b> Begin exercise, sauna, and steam bath restrictions	<b>11</b> Begin alcohol restrictions Begin exercise, sauna, and steam bath restrictions
<b>12</b> Begin overnight fast Begin alcohol restrictions	<b>13</b> Day -1 Admission Begin overnight fast	<b>14</b> Day 1 Dose Day -1 Admission	<b>15</b> Day 2 Inpatient Day 1 Dose	<b>16</b> Day 3 Inpatient Day 2 Inpatient	<b>17</b> Day 4 Discharge Payment 1* Day 3 Inpatient	<b>18</b> Day 4 Discharge Payment 1* Begin exercise, sauna, and steam bath restrictions
<b>19</b> Begin exercise, sauna, and steam bath restrictions	<b>20</b> Begin overnight fast	<b>21</b> Day 8 OPV Begin overnight fast	<b>22</b> Day 8 OPV	<b>23</b>	<b>24</b>	<b>25</b> Begin exercise, sauna, and steam bath restrictions
<b>26</b> Begin exercise, sauna, and steam bath restrictions	<b>27</b> Begin overnight fast	<b>28</b> Day 15 OPV Payment 2* Begin overnight fast	<b>29</b> Day 15 OPV Payment 2*	<b>30</b>		

**Study Inpatient dates:**  
Sentinels: Apr 13-17, 2026  
Non-Sentinels: Apr 14-18, 2026  
**Study Outpatient dates:**  
Sentinels: Apr 21 and 28, 2026  
May 05, 12, 26, 2026  
Jun 09, Jul 07, Aug 04, Sep 01, Sep 29, 2026  
Non-Sentinels: Apr 22 and 29, 2026  
May 06, 13, 27, 2026  
Jun 10, Jul 08, Aug 05, Sep 02, Sep 30, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to Admission (Day -1) and required study visits (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI: A staff member from Cincinnati Children’s will contact you with further details.**

**May 2026**

**MEDPACE**  
Clinical Pharmacology

**SRK-439-001 SAD Cohort 5 Sentinels & Non-Sentinels**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
					<b>1</b>	<b>2</b> Begin exercise, sauna, and steam bath restrictions
<b>3</b> Begin exercise, sauna, and steam bath restrictions	<b>4</b> Begin overnight fast	<b>5</b> <b>Day 22 OPV</b> Begin overnight fast	<b>6</b> <b>Day 22 OPV</b>	<b>7</b>	<b>8</b>	<b>9</b> Begin exercise, sauna, and steam bath restrictions
<b>10</b> <b>Day 29 MRI Window Opens*</b> Begin exercise, sauna, and steam bath restrictions	<b>11</b> Begin overnight fast <b>Day 29 MRI Window Opens*</b>	<b>12</b> <b>Day 29 OPV Payment 3*</b> <b>MRI Window Closes*</b> Begin overnight fast	<b>13</b> <b>Day 29 OPV Payment 3*</b> <b>MRI Window Closes*</b>	<b>14</b>	<b>15</b>	<b>16</b>
<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>	<b>23</b> Begin exercise, sauna, and steam bath restrictions
<b>24</b> Begin exercise, sauna, and steam bath restrictions	<b>25</b> Begin overnight fast	<b>26</b> <b>Day 43 OPV Payment 4*</b> Begin overnight fast	<b>27</b> <b>Day 43 OPV Payment 4*</b>	<b>28</b>	<b>29</b>	<b>30</b>
<b>31</b>						

**Study Inpatient dates:**

Sentinels: Apr 13-17, 2026

Non-Sentinels: Apr 14-18, 2026

**Study Outpatient dates:**

Sentinels: Apr 21 and 28, 2026

May 05, 12, 26, 2026

Jun 09, Jul 07, Aug 04, Sep 01, Sep 29, 2026

Non-Sentinels: Apr 22 and 29, 2026

May 06, 13, 27, 2026

Jun 10, Jul 08, Aug 05, Sep 02, Sep 30, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to Admission (Day -1) and required study visits (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI: A staff member from Cincinnati Children's will contact you with further details.**

# June 2026

## MEDPACE

Clinical Pharmacology

### SRK-439-001 SAD Cohort 5 Sentinels & Non-Sentinels

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b> Begin exercise, sauna, and steam bath restrictions
<b>7</b> <b>Day 57 MRI Window Opens*</b> Begin exercise, sauna, and steam bath restrictions	<b>8</b> Begin overnight fast <b>Day 57 MRI Window Opens*</b>	<b>9</b> <b>Day 57 OPV Payment 5*</b> <b>MRI Window Closes*</b> Begin overnight fast	<b>10</b> <b>Day 57 OPV Payment 5*</b> <b>MRI Window Closes*</b>	<b>11</b>	<b>12</b>	<b>13</b>
<b>14</b>	<b>15</b>	<b>16</b>	<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b>
<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>	<b>25</b>	<b>26</b>	<b>27</b>
<b>28</b>	<b>29</b>	<b>30</b>				

**Study Inpatient dates:**  
Sentinels: Apr 13-17, 2026  
Non-Sentinels: Apr 14-18, 2026

**Study Outpatient dates:**  
Sentinels: Apr 21 and 28, 2026  
May 05, 12, 26, 2026  
Jun 09, Jul 07, Aug 04, Sep 01, Sep 29, 2026  
Non-Sentinels: Apr 22 and 29, 2026  
May 06, 13, 27, 2026  
Jun 10, Jul 08, Aug 05, Sep 02, Sep 30, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to Admission (Day -1) and required study visits (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI: A staff member from Cincinnati Children's will contact you with further details.**

**July 2026**

**MEDPACE**  
Clinical Pharmacology

**SRK-439-001 SAD Cohort 5 Sentinels & Non-Sentinels**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b> Begin exercise, sauna, and steam bath restrictions
<b>5</b> Begin exercise, sauna, and steam bath restrictions	<b>6</b> Begin overnight fast	<b>7</b> <b>Day 85 OPV Payment 6*</b> Begin overnight fast	<b>8</b> <b>Day 85 OPV Payment 6*</b>	<b>9</b>	<b>10</b>	<b>11</b>
<b>12</b>	<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b>	<b>17</b>	<b>18</b>
<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>	<b>25</b>
<b>26</b>	<b>27</b>	<b>28</b>	<b>29</b>	<b>30</b>	<b>31</b>	

**Study Inpatient dates:**  
Sentinels: Apr 13-17, 2026  
Non-Sentinels: Apr 14-18, 2026  
**Study Outpatient dates:**  
Sentinels: Apr 21 and 28, 2026  
May 05, 12, 26, 2026  
Jun 09, Jul 07, Aug 04, Sep 01, Sep 29, 2026  
Non-Sentinels: Apr 22 and 29, 2026  
May 06, 13, 27, 2026  
Jun 10, Jul 08, Aug 05, Sep 02, Sep 30, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to Admission (Day -1) and required study visits (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI: A staff member from Cincinnati Children's will contact you with further details.**

**August 2026**

**MEDPACE**  
Clinical Pharmacology

**SRK-439-001 SAD Cohort 5 Sentinels & Non-Sentinels**

Sun	Mon	Tue	Wed	Thu	Fri	Sat
						<b>1</b> Begin exercise, sauna, and steam bath restrictions
<b>2</b> Begin exercise, sauna, and steam bath restrictions	<b>3</b> Begin overnight fast	<b>4</b> <b>Day 113 OPV Payment 7*</b> Begin overnight fast	<b>5</b> <b>Day 113 OPV Payment 7*</b>	<b>6</b>	<b>7</b>	<b>8</b>
<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>	<b>13</b>	<b>14</b>	<b>15</b>
<b>16</b>	<b>17</b>	<b>18</b>	<b>19</b>	<b>20</b>	<b>21</b>	<b>22</b>
<b>23</b>	<b>24</b>	<b>25</b>	<b>26</b>	<b>27</b>	<b>28</b>	<b>29</b> Begin exercise, sauna, and steam bath restrictions
<b>30</b> Begin exercise, sauna, and steam bath restrictions	<b>31</b> Begin overnight fast					

**Study Inpatient dates:**

Sentinels: Apr 13-17, 2026

Non-Sentinels: Apr 14-18, 2026

**Study Outpatient dates:**

Sentinels: Apr 21 and 28, 2026

May 05, 12, 26, 2026

Jun 09, Jul 07, Aug 04, Sep 01, Sep 29, 2026

Non-Sentinels: Apr 22 and 29, 2026

May 06, 13, 27, 2026

Jun 10, Jul 08, Aug 05, Sep 02, Sep 30, 2026

**Instructions / Restrictions:**

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1).**
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening.**
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening .**
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study.**
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study.**
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening.**
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1).**
- Avoid medications that impede coagulation or platelet aggregation **throughout the study.**
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening.**
- Avoid strenuous exercise for **72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study.**
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study.**
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study.**
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study.**
- Avoid the use of saunas or steam baths **within 72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to Admission (Day -1) and required study visits (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169).**

**Reminder:** COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI: A staff member from Cincinnati Children’s will contact you with further details.**

# September 2026

## MEDPACE Clinical Pharmacology

### SRK-439-001 SAD Cohort 5 Sentinels & Non-Sentinels

Sun	Mon	Tue	Wed	Thu	Fri	Sat
		<b>1</b> <b>Day 141 OPV</b> <b>Payment 8*</b> Begin overnight fast	<b>2</b> <b>Day 141 OPV</b> <b>Payment 8*</b>	<b>3</b>	<b>4</b>	<b>5</b>
<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>10</b>	<b>11</b>	<b>12</b>
<b>13</b>	<b>14</b>	<b>15</b>	<b>16</b>	<b>17</b>	<b>18</b>	<b>19</b>
<b>20</b>	<b>21</b>	<b>22</b>	<b>23</b>	<b>24</b>	<b>25</b>	<b>26</b> Begin exercise, sauna, and steam bath restrictions
<b>27</b> <b>Day 169 MRI Window Opens*</b> Begin exercise, sauna, and steam bath restrictions	<b>28</b> Begin overnight fast <b>Day 169 MRI Window Opens*</b>	<b>29</b> <b>Day 169 OPV (EOS)</b> <b>Payment 9*</b> <b>MRI Window Closes*</b> Begin overnight fast	<b>30</b> <b>Day 169 OPV (EOS)</b> <b>Payment 9*</b> <b>MRI Window Closes*</b>			

#### Study Inpatient dates:

Sentinels: Apr 13-17, 2026

Non-Sentinels: Apr 14-18, 2026

#### Study Outpatient dates:

Sentinels: Apr 21 and 28, 2026

May 05, 12, 26, 2026

Jun 09, Jul 07, Aug 04, Sep 01, Sep 29, 2026

Non-Sentinels: Apr 22 and 29, 2026

May 06, 13, 27, 2026

Jun 10, Jul 08, Aug 05, Sep 02, Sep 30, 2026

#### Instructions / Restrictions:

- Continue to follow birth control requirements outlined in the consent form **throughout the study and for 24 weeks after the last dose of study drug (Day 1)**.
- Avoid treatment with SRK-439 or apitegromab or with other anti-myostatin therapies, including ACTR antagonists **prior to Screening**.
- Avoid exposure to immunosuppressive, chemotherapeutic, or radiation treatment **within 12 months prior to Screening**.
- Avoid the use of anabolic steroids, growth hormones, or other substances with known muscle effects **prior to Screening and throughout the study**.
- Avoid the use of therapies with significant muscle effects (e.g., insulin-like growth factor, systemic beta-agonist, neurotoxins, or muscle relaxants or muscle-enhancing supplements) in any form **within 3 months prior to Screening and during the study**.
- Avoid use of systemic or intra-articular corticosteroids (inhaled or topical steroids are allowed) **within 60 days prior to Screening**.
- Avoid prescription (hormonal contraceptives allowed), over-the-counter medications (OTC analgesics (e.g., paracetamol and NSAIDs, less than or equal to 2.4 g/day) allowed **with permission of Investigator**, and use of over-the-counter products (including dietary or herbal supplements and vitamins) **within 14 days prior to Admission (Day -1)**.
- Avoid medications that impede coagulation or platelet aggregation **throughout the study**.
- Avoid treatment with other investigational drugs or devices in a clinical study or exposure to a biologic therapeutic **within 3 months or 5 half-lives, whichever is longer, prior to Screening**.
- Avoid strenuous exercise for **72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169)**.
- Avoid alcohol **within 48 hours prior to Admission (Day -1) and throughout the study**.
- Avoid excessive alcohol consumption (defined as > 14 drinks/week for men and > 7 drinks/week for women) and illicit drug use **12 months prior to Admission (Day -1) and throughout the study**.
- Avoid use of inhaled vasoconstrictive tobacco or cannabis or synthetic products such as vape pens, pipes, cigars, and cigarettes **3 months prior to Admission (Day -1) and throughout the study**.
- Avoid donation of 500mL (1 pint) or more of blood **within 8 weeks** or 600 mL (2.5 cups) or more of plasma **within 14 days prior to Screening and throughout the study**.
- Avoid the use of saunas or steam baths **within 72 hours prior to Admission (Day -1) and each clinic visit (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169)**.
- Fast overnight for **at least 10 hours (no food or liquids other than water) prior to Admission (Day -1) and required study visits (Days 8, 15, 22, 29, 43, 57, 85, 113, 141, and 169)**.

Reminder: COVID-19 rapid antigen test, breath alcohol, cotinine & urine drug test at Day -1 Admission.

**\*payment to occur within 48 hours after payment visit day**

**\*MRI: A staff member from Cincinnati Children's will contact you with further details.**